Device Trial Radar · NCT03884647
DELPHI in Subjects at Risk for Stroke and Dementia
Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
335
Actual
Start
Apr 1, 2020
Primary completion
May 6, 2022
Study completion May 6, 2022
Sponsor
- Lead sponsor
- QuantalX NeuroscienceNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 21, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories. Standard electro-physiological acquisition is performed using TMS to evoke regional neuronal potentials measured as EEG data. TMS-EEG data is analyzed with regards to conventional, well established characteristics of neuronal network plasticity and connectivity.
Conditions
- Stroke
- Hypertension
- Diabete Mellitus
- Dyslipidemias
- Sleep Disorder
- Smoking
- Overweight and Obesity
- Familial Alzheimer Disease
- Atrial Fibrillation
- Cardiac Disease
- Cognitive Impairment
- Transient Ischemic Attack
Interventions
DELPhI systemDevice
DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Establishing DELPhI's norms of population 50-75 years old at risk for stroke and dementiaTime frame: 1 visit
2 more outcomes with a free account
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Diablo Clinical Research Inc.
Walnut Creek, California
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.